Drug Trial Radar · NCT03910621
Safety and Efficacy of Miglustat in Chinese NPC Patients
Last checked: Nov 20, 2026Latest source record: Mar 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
17
Actual
Start
Apr 2, 2020
Primary completion
Mar 25, 2022
Study completion Mar 25, 2022
Sponsor
- Lead sponsor
- ActelionJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Apr 10, 2019
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 4 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, multi-center, open-label, non-randomized, single-arm Phase IV confirmatory study. Approximately 19 subjects with Niemann Pick Type C disease (NPC) will be enrolled in this study. The study will be conducted at 2 sites in China.
Conditions
- Niemann-Pick Disease, Type C
Interventions
MiglustatDrug
capsule, oral use
Primary outcomes
What the sponsor says the trial is designed to measure.
- Observed change in HSEM (ms/deg)Time frame: baseline to week 52
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Peking University first Hospital
Beijing, China
Xin Hua Hospital, Shanghai Jiao Tong University
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.